Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2

• Main Authors: Ryan W. Stevens, PharmD, Christina G. Rivera, PharmD, Omar Abu Saleh, MBBS
• Format: Article
• Language: English
• Published: Elsevier 2020-12-01
• Series: Mayo Clinic Proceedings: Innovations, Quality & Outcomes
• Online Access: http://www.sciencedirect.com/science/article/pii/S2542454820301934

In many different infectious syndromes, most notably several viral conditions, time to therapy initiation from symptom onset has been identified as a critical component contributing to the success of therapy. Regarding COVID-19, several therapeutic antivirals, both repurposed and novel, have been evaluated for overall safety and efficacy. As the literature related to these therapies has expanded recently, a wide array of trial designs, time to therapy initiation thresholds, and clinical outcomes in regard to time to initiation have been reported. We describe the potential effects of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine.